MSF’s pricing guide to purchasing ARVs: 8th edition online
14 July 2005. Related: Treatment access.
On June 28 Medecins sans Frontiers (MSF) published the 8th edition of ‘Untangling the web of price reductions: a pricing guide for the purchase of ARVs in developing countries’.
The report shows that while generic production has brought down the prices of most first-line antiretrovirals (ARVs) from over $10,000 in 2000 to as little as $150 per patient in June 2005, prices of newer ARVs and formulations for children are up to 12 times higher.
It focuses on the political issues relating to drug pricing and trade agreements that threaten access to generic medication; and the importance of access to newer drugs and affordable second-line therapy for management of treatment failure and drug toxicity.